ACAvinash Chennamsetty

Avinash Chennamsetty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Avinash Chennamsetty has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Jonathan Yamzon

    Department of Surgery, Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA, USA

    3 shared publications
  • Kim A. Killinger

    Department of Urology, Beaumont Health System, Royal Oak, MI, USA

    3 shared publications
  • Nora Ruel

    Department of Computation and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA 91010, USA

    3 shared publications
  • Ali Zhumkhawala

    Department of Surgery, Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA, USA

    2 shared publications
  • Bertram Yuh

    Department of Surgery, Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA, USA

    2 shared publications
  • Clayton Lau

    Department of Surgery, Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA, USA

    2 shared publications

Latest Publications

  • Prospective randomised non‐inferiority trial of pelvic drain placement vs no pelvic drain placement after robot‐assisted radical prostatectomy

    by Avinash Chenam, Bertram Yuh, Ali Zhumkhawala, Nora Ruel, William Chu, Clayton Lau, Kevin Chan, Timothy Wilson, Jonathan Yamzon

    Objective: To determine if eliminating the prophylactic placement of a pelvic drain ( PD ) after robot‐assisted radical prostatectomy ( RARP ) affects the incidence of early (90‐day) postoperative adverse events. Patients and Methods: In this parallel‐group, blinded, non‐inferiority trial, we randomised patients planning to undergo RARP to one of two arms: no drain placement ( ND ) or PD placement. Patients with demonstrable intraoperative leakage upon bladder irrigation were excluded. Randomisation sequence was determined a priori using a computer algorithm, and included a stratified design with respect to low vs intermediate/high D'Amico risk classifications. Surgeons remained blinded to the randomisation arm until final eligibility was verified at the end of the RARP . The primary endpoint was overall incidence of 90‐day complications which, based on our standard treatment using PD retrospectively, was estimated at 13%. The non‐inferiority margin was set at 10%, and the planned sample size was 312. An interim analysis was planned and conducted when one‐third of the planned accrual and follow‐up was completed, to rule out futility if the delta margin was in excess of 0.1389. Results: From 2012 to 2016, 189 patients were accrued to the study, with 92 patients allocated to the ND group and 97 to the PD group. Due to lower than expected accrual rates, accrual to the study was halted by regulatory entities, and we did not reach the intended accrual goal. The ND and PD groups were comparable for median PSA level (6.2 vs 5.8 ng/ mL , P = 0.5), clinical stage ( P = 0.8), D'Amico risk classification ( P = 0.4), median lymph nodes dissected (17 vs 18, P = 0.2), and proportion of patients receiving an extended pelvic lymph node dissection (70.7% vs 79.4%, P = 0.3). Incidence of 90‐day overall and major (Clavien–Dindo grade > III ) complications in the ND group (17.4% and 5.4%, respectively) was not inferior to the PD group (26.8% and 5.2%, respectively; P < 0.001 and P = 0.007 for difference of proportions P = 0.7). Conclusions: Incidence of adverse events in the ND group was not inferior to the group who received a PD . In properly selected patients, PD placement after RARP can be safely withheld without significant additional morbidity.


  • Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy

    by Avinash Chenam, Jaspreet S. Parihar, Nora Ruel, Sumanta Pal, Yvonne Avila, Jonathan Yamzon, Clayton Lau, Bertram Yuh

    Optimal management of node-positive prostate cancer patients after prostatectomy remains a challenge. We evaluated clinically localized patients who demonstrated node positivity and identified predictors for secondary treatment. From 2010 to 2015, clinically localized prostate cancer patients who underwent robot prostatectomy with extended lymphadenectomy and node-positive disease on pathologic analysis were identified. Clinical N1, M1 or salvage cases were excluded. Patients were stratified based on secondary treatments. Kaplan–Meier method was used to determine the time to biochemical and metastatic recurrence. Multivariate logistic regression was used to identify predictors for additional treatment. 145 patients (45 no additional therapy, 47 adjuvant, 53 salvage) had a median follow-up of 31.2 months. Salvage patients had higher median pre-operative prostate-specific antigen (10.8 vs. 9.7 vs. 8.2, p = 0.1), higher percentage of pathologic Gleason ≥8 (50.9 vs. 38.3% and 22.2%, p < 0.01), and higher median-positive nodes (3 vs. 1 and 1, p < 0.0001) compared to adjuvant and no treatment groups, respectively. Pathologic Gleason ≥8 (OR = 3.5, p = 0.007) and positive nodes ≥2 (OR = 3.3, p = 0.006) were associated with additional therapy. In the no treatment group, two-year estimated BCRFS was 74.3%. Two-year metastatic recurrence-free rates for no treatment, adjuvant and salvage groups were 100, 87.5, and 80.9%, respectively (p = 0.01). Observation is a viable alternative for low metastatic burden patients. In the largest series of node-positive patients from robotic prostatectomy and extended lymphadenectomy, those with pathologic Gleason ≥8 and positive lymph nodes ≥2 were more likely to receive additional treatment.


  • Lymph Node Fluorescence During Robot-Assisted Radical Prostatectomy With Indocyanine Green: Prospective Dosing Analysis

    by Avinash Chennamsetty, Ali Zhumkhawala, Scott B. Tobis, Nora Ruel, Clayton S. Lau, Jonathan Yamzon, Timothy G. Wilson, Bertram E. Yuh


  • Open Access

    Contemporary diagnosis and management of Fournier’s gangrene

    by Avinash Chennamsetty, Iyad Khourdaji, Frank Burks, Kim A. Killinger

    Fournier’s gangrene, an obliterative endarteritis of the subcutaneous arteries resulting in gangrene of the overlying skin, is a rare but severe infective necrotizing fasciitis of the external genitalia. Mainly associated with men and those over the age of 50, Fournier’s gangrene has been shown to have a predilection for patients with diabetes as well as people who are long-term alcohol misusers. The nidus for the synergistic polymicrobial infection is usually located in the genitourinary tract, lower gastointestinal tract or skin. Early diagnosis remains imperative as rapid progression of the gangrene can lead to multiorgan failure and death. The diagnosis is often made clinically, although radiography can be helpful when the diagnosis or the extent of the disease is difficult to discern. The Laboratory Risk Indicator for Necrotizing Fasciitis score can be used to stratify patients into low, moderate or high risk and the Fournier’s Gangrene Severity Index (FGSI) can also be used to determine the severity and prognosis of Fournier’s gangrene. Mainstays of treatment include rapid and aggressive surgical debridement of necrotized tissue, hemodynamic support with urgent resuscitation with fluids, and broad-spectrum parental antibiotics. After initial radical debridement, open wounds are generally managed with sterile dressings and negative-pressure wound therapy. In cases of severe perineal involvement, colostomy has been used for fecal diversion or alternatively, the Flexi-Seal Fecal Management System can be utilized to prevent fecal contamination of the wound. After extensive debridement, many patients sustain significant defects of the skin and soft tissue, creating a need for reconstructive surgery for satisfactory functional and cosmetic results.


  • Open Access

    Predictors of Incisional Hernia after Robotic Assisted Radical Prostatectomy

    by Avinash Chennamsetty, Jason Hafron, Luke Edwards, Scott Pew, Behdod Poushanchi, Jay Hollander, Kim A. Killinger, Mary P. Coffey, Kenneth M. Peters

    Introduction.To explore the long term incidence and predictors of incisional hernia in patients that had RARP.Methods.All patients who underwent RARP between 2003 and 2012 were mailed a survey reviewing hernia type, location, and repair.Results.Of 577 patients, 48 (8.3%) had a hernia at an incisional site (35 men had umbilical), diagnosed at (median) 1.2 years after RARP (mean follow-up of 5.05 years). No statistically significant differences were found in preoperative diabetes, smoking, pathological stage, age, intraoperative/postoperative complications, operative time, blood loss, BMI, and drain type between patients with and without incisional hernias. Incisional hernia patients had larger median prostate weight (45 versus 38 grams;P=0.001) and a higher proportion had prior laparoscopic cholecystectomy (12.5% (6/48) versus 4.6% (22/480);P=0.033). Overall, 4% (23/577) of patients underwent surgical repair of 24 incisional hernias, 22 umbilical and 2 other port site hernias.Conclusion.Incisional hernia is a known complication of RARP and may be associated with a larger prostate weight and history of prior laparoscopic cholecystectomy. There is concern about the underreporting of incisional hernia after RARP, as it is a complication often requiring surgical revision and is of significance for patient counseling before surgery.


  • Open Access

    Treatment of Urethral Strictures from Irradiation and Other Nonsurgical Forms of Pelvic Cancer Treatment

    by Iyad Khourdaji, Jacob Parke, Avinash Chennamsetty, Frank Burks

    Radiation therapy (RT), external beam radiation therapy (EBRT), brachytherapy (BT), photon beam therapy (PBT), high intensity focused ultrasound (HIFU), and cryotherapy are noninvasive treatment options for pelvic malignancies and prostate cancer. Though effective in treating cancer, urethral stricture disease is an underrecognized and poorly reported sequela of these treatment modalities. Studies estimate the incidence of stricture from BT to be 1.8%, EBRT 1.7%, combined EBRT and BT 5.2%, and cryotherapy 2.5%. Radiation effects on the genitourinary system can manifest early or months to years after treatment with the onus being on the clinician to investigate and rule-out stricture disease as an underlying etiology for lower urinary tract symptoms. Obliterative endarteritis resulting in ischemia and fibrosis of the irradiated tissue complicates treatment strategies, which include urethral dilation, direct-vision internal urethrotomy (DVIU), urethral stents, and urethroplasty. Failure rates for dilation and DVIU are exceedingly high with several studies indicating that urethroplasty is the most definitive and durable treatment modality for patients with radiation-induced stricture disease. However, a detailed discussion should be offered regarding development or worsening of incontinence after treatment with urethroplasty. Further studies are required to assess the nature and treatment of cryotherapy and HIFU-induced strictures.


  • Electrosurgical Management of Hunner Ulcers in a Referral Center's Interstitial Cystitis Population

    by Avinash Chennamsetty, Iyad Khourdaji, Jonathan Goike, Kim A. Killinger, Benjamin Girdler, Kenneth M. Peters


  • Advances in Diagnosis and Treatment of Interstitial Cystitis/Painful Bladder Syndrome

    by Avinash Chennamsetty, Michael J. Ehlert, Kenneth M. Peters, Kim A. Killinger

    Interstitial cystitis/bladder pain syndrome (IC/BPS) is a prevalent chronic condition that can be challenging not only to diagnose but also to treat. We review recent diagnostic markers and therapies for IC/BPS from non-medication-based therapies, oral therapies, intravesical therapies, and surgical treatments.


  • Open Access

    Removal of a Penile Constriction Device with a Large Orthopedic Pin Cutter

    by Avinash Chennamsetty, David Wenzler, Melissa Fischer

    Penile strangulation is an infrequent clinical condition that has widely been reported. It usually results following placement of a constriction device to enhance sexual stimulation. Early treatment is essential to avoid potential complications, including ischemic necrosis and autoamputation. We describe the use of a Large Orthopedic Pin Cutter to remove a metal penile constriction device in the Emergency Department (ED). This case report describes the relatively safe technique of using an instrument available in many hospitals that can be added to the physician’s arsenal in the removal of metal constriction devices.